Viatris plans for Ozempic, Wegovy generics amid lawsuit from Novo Nordisk over Wegovy
2023-08-07
专利侵权
Viatris Pharmaceuticals’ applications for generic options for type 2 diabetes drug Ozempic and weight loss drug Wegovy are now under regulatory review, according to
the company’s second quarter presentation
.
If approved, both would be the first generics to market for the blockbuster drugs.
But Novo Nordisk has already taken steps to stop ViatrisViatris from bringing a Wegovy generic to market with a lawsuit filed in January in Delaware District Court. In court filings, lawyers for Novo wrote that the lawsuit comes from Viatris’ submission of an abbreviated NDA to the FDA for a Wegovy generic injection prior to the patents’ expiration.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。